HAINAN HAIYAO CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.58 CNY | +2.29% |
|
+7.51% | -20.80% |
| Sales 2022 | 1.78B 246M 20.5B | Sales 2023 | 1.48B 204M 17.04B | Capitalization | 5.86B 810M 67.57B |
|---|---|---|---|---|---|
| Net income 2022 | 10M 1.38M 115M | Net income 2023 | -106M -14.64M -1.22B | EV / Sales 2022 | 4.84 x |
| Net Debt 2022 | 3.08B 425M 35.45B | Net cash position 2023 * | - 0 0 | EV / Sales 2023 | 3.97 x |
| P/E ratio 2022 |
527
x | P/E ratio 2023 |
-55.1
x | Employees | 2,247 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 58.32% |
More Fundamentals
* Assessed data
More news
| 1 day | +2.29% | ||
| 1 week | +7.51% | ||
| Current month | -3.24% | ||
| 1 month | -3.24% | ||
| 3 months | -11.82% | ||
| 6 months | -21.32% | ||
| Current year | -20.80% |
1 week
3.32
3.60
1 month
3.163.82
Current year
2.904.66
1 year
2.905.59
3 years
2.906.31
5 years
2.9011.50
10 years
2.9027.64
| Managers | Title | Age | Since |
|---|---|---|---|
Jun Hong Wang
CEO | Chief Executive Officer | 55 | 08/22/08 |
Rong Yi Xu
DFI | Director of Finance/CFO | 53 | 29/21/29 |
Jian Min Zhang
CTO | Chief Tech/Sci/R&D Officer | 46 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Xi Cheng Liu
BRD | Director/Board Member | 62 | 16/05/16 |
Duo Jia Feng
BRD | Director/Board Member | 66 | - |
Jun Hong Wang
CEO | Chief Executive Officer | 55 | 08/22/08 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +2.43% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/24/29 | 3.58 | +2.29% | 9,032,004 |
| 26/24/26 | 3.5 | +1.74% | 7,053,229 |
| 25/24/25 | 3.44 | +1.47% | 6,446,432 |
| 24/24/24 | 3.39 | 0.00% | 6,520,387 |
| 23/24/23 | 3.39 | +1.80% | 6,904,800 |
End-of-day quote Shenzhen S.E., April 29, 2024
More quotes
HAINAN HAIYAO CO., LTD. is a China-based company principally engaged in the research, development, manufacture and sale of medicines and medical instrument. The Companyâs main products consist of six categories, including cephalosporin series, stomach and intestine medicines, anti-tumor medicines, cochlear implant series, bulk drugs and intermediate series. The Company distributes its products in domestic market and to overseas market, with China as its main market.
Sector
Pharmaceuticals
Calendar
30/04/2024
- Q1 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -20.80% | 642M | |
| +26.47% | 664B | |
| +30.31% | 567B | |
| -6.33% | 354B | |
| +19.35% | 330B | |
| +4.23% | 286B | |
| +14.34% | 234B | |
| +4.94% | 199B | |
| -10.10% | 196B | |
| -4.04% | 148B |
- Stock Market
- Equities
- 000566 Stock
